Metronidazole Decreases Viability of DLD-1 Colorectal Cancer Cell Line

Abstract

The aim of our study was to evaluate the impact of metronidazole (MTZ) on DLD-1 colorectal cancer cell (CRC) line. Toxicity of MTZ was determined by MTT test. Cells were incubated with MTZ used in different concentrations for 24, 48, and 72 hours. The effect of MTZ on DNA synthesis was measured as [3H]-thymidine incorporation. The morphological changes in human DLD-1 cell line were defined by transmission electron microscope OPTON 900. The influence of MTZ on the apoptosis of DLD-1 cell lines was detected by flow cytometry and fluorescence microscopy, while cell concentration, volume, and diameter were displayed by Scepter Cell Counter from Millipore. Our results show that cell viability was diminished in all experimental groups in comparison with the control, and the differences were statistically significant. We did not find any significant differences in [3H]-thymidine incorporation in all experimental groups and times of observation. Cytofluorimetric assays demonstrated a statistically significant increase of apoptotic rate in MTZ concentrations 10 and 50 lg/mL after 24 hours; 0.1, 10, 50, and 250 lg/mL after 48 hours; and in all concentrations after 72 hours compared with control groups. In the ultrastructural studies, necrotic or apoptotic cells were occasionally seen. In conclusion, MTZ affects human CRC cell line viability. The reduction of cell viability was consistent with the apoptotic test.

The Effect of Metronidazole on the Viability of Cal-27 Tongue Cancer Cells.

“…Although, the conditions of the research was analogical to those in our research, the outcome was quite opposite ñ authors found the decrease in the viability of cells, depending on the concentration of the drug and time of incubation, with the highest value reaching 20%. In the same study authors evaluated differences in DNA synthesis using the [ 3 H]-thymidine incorporation test, which demonstrated no statistically significant changes in comparison with control cells (22). The result of the analogical test in our study was similar.…”

Untitled

“…In another reported article it was evaluated for its cytotoxic activity on DLD-1 colorectal cancer cell lines. They reported that the cell viability was decreased in all experimental groups when compared to control and found statistically significant 8 . MT also proved its cytotoxic potential on breast cancer cell lines, Sadowski et al reported the impact of cytotoxicity of MT on MCF-7 and MDA-MB-231 breast cancer cell lines 9 .…”

Effects of metronidazole on colorectal cancer occurrence and colorectal cancer liver metastases by regulating Fusobacterium nucleatum in mice

“…F. nucleatum infections are routinely treated by MNZ 25 . MNZ represses the cell viability of DLD‐1 CRC cell lines 24 . Some therapies, such as probiotics, diets, prebiotics, stool microbiota transplantation, ursodeoxycholic acid, and engineered bacteria, can mitigate inflammatory bowel diseases by means of bile acids and gut microbiota restoration 40 .…”

“…Fibroblast activating protein 2 (Fap2) is an essential membrane protein for F. nucleatum that can encourage bacterial adhesion to colon cells, recruit immune cells, and lead to tumor development, and designing a vaccine candidate containing Fap2 B‐ and T‐cell epitopes may serve as a promising therapeutic approach to intervene in F. nucleatum ‐induced human CRC 23 . Metronidazole (MNZ) is a pivotal drug for a variety of infections, which are induced by anaerobic bacteria, besides, MTZ reduced cell viability of DLD‐1 cell lines 24 . F. nucleatum infections are routinely treated by MNZ 25 .…”

“… 23 Metronidazole (MNZ) is a pivotal drug for a variety of infections, which are induced by anaerobic bacteria, besides, MTZ reduced cell viability of DLD‐1 cell lines. 24 F. nucleatum infections are routinely treated by MNZ. 25 F. nucleatum induces tumor to resist to immunotherapy, while antibiotic MNZ treatment is able to reduce the abundance of F. nucleatum , making tumors re‐sensitive to immunotherapy in vivo.…”